Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. India
  4. Bombay Stock Exchange
  5. Syngene International Limited
  6. News
  7. Summary
    539268   INE398R01022

SYNGENE INTERNATIONAL LIMITED

(539268)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Syngene International Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020

01/20/2021 | 12:43pm EDT

Syngene International Limited announced earnings results for the third quarter ended December 31, 2020. For the third quarter, the company announced total revenue was INR 6,016 million compared to INR 5,391 million a year ago. Net income was INR 1,022 million compared to INR 918 million a year ago. Basic earnings per share from continuing operations was INR 2.57 compared to INR 2.32 a year ago. Diluted earnings per share from continuing operations was INR 2.55 compared to INR 2.31 a year ago. For the nine months, total revenue was INR 15,719 million compared to INR 14,657 million a year ago. Net income was INR 2,443 million compared to INR 2,919 million a year ago. Basic earnings per share from continuing operations was INR 6.14 compared to INR 7.35 a year ago. Diluted earnings per share from continuing operations was INR 6.1 compared to INR 7.33 a year ago.


© S&P Capital IQ 2021
All news about SYNGENE INTERNATIONAL LIMITED
02:09aSYNGENE INTERNATIONAL : Logs 21% Drop in Consolidated Net Profit in Fiscal Q2; Shares Slid..
MT
07/20SYNGENE INTERNATIONAL : Consolidated Net Profit Climbs in Fiscal Q1
MT
07/20Syngene International Limited Announces Resignation of John M M Shaw from the Board of ..
CI
07/20Syngene International Limited Reports Earnings Results for the First Quarter Ended June..
CI
06/22Syngene International Limited Appoints Dr. Kush Parmar as an Additional Director (Indep..
CI
05/26DYADIC INTERNATIONAL : Syngene to Join Forces for COVID-19 Vaccine Production
MT
05/26SYNGENE INTERNATIONAL : Dyadic announces development of COVID-19 Vaccine in India
AQ
05/26Dyadic International, Inc. Enters into Collaboration with Syngene International Limited
CI
04/28BIOCON : Syngene targets delivering 500,000 vials of remdesivir in India as COVID-19 surge..
RE
04/28SYNGENE INTERNATIONAL : Posts Higher Profit in January-March
MT
More news
Financials
Sales 2022 26 105 M 349 M 349 M
Net income 2022 4 111 M 54,9 M 54,9 M
Net cash 2022 4 104 M 54,8 M 54,8 M
P/E ratio 2022 58,0x
Yield 2022 0,08%
Capitalization 236 B 3 152 M 3 151 M
EV / Sales 2022 8,88x
EV / Sales 2023 7,61x
Nbr of Employees 5 437
Free-Float 28,7%
Chart SYNGENE INTERNATIONAL LIMITED
Duration : Period :
Syngene International Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SYNGENE INTERNATIONAL LIMITED
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 594,85 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Jonathan Hunt Chief Executive Officer, MD & Executive Director
Sibaji Biswas Chief Financial Officer
Kiran Mazumdar-Shaw Non-Executive Chairman
Mahesh K Bhalgat Chief Operating Officer
Priyadarshini I. Mahapatra Secretary & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
SYNGENE INTERNATIONAL LIMITED-7.00%3 213
MODERNA, INC.225.04%134 418
LONZA GROUP AG29.18%59 339
IQVIA HOLDINGS INC.42.23%48 194
SEAGEN INC.-0.71%31 811
CELLTRION, INC.-39.42%25 446